65/100 · Elevated
Manufactured by Novartis Pharmaceuticals Corporation
Fingolimod HCL Adverse Events: Moderate Safety Concerns
175,367 FDA adverse event reports analyzed
Last updated: 2026-05-12
FINGOLIMOD HCL is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Novartis Pharmaceuticals Corporation. Based on analysis of 175,367 FDA adverse event reports, FINGOLIMOD HCL has a safety score of 65 out of 100. This moderate score indicates a notable volume of adverse event reports that patients and providers should be aware of. The most commonly reported adverse reactions for FINGOLIMOD HCL include FATIGUE, MULTIPLE SCLEROSIS RELAPSE, HEADACHE, DIZZINESS, WHITE BLOOD CELL COUNT DECREASED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for FINGOLIMOD HCL.
Fingolimod Hcl has a safety concern score of 65 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 175,367 adverse event reports for this medication, which is primarily manufactured by Novartis Pharmaceuticals Corporation.
The most commonly reported adverse events include Fatigue, Multiple Sclerosis Relapse, Headache. Of classified reports, 51.3% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Fingolimod HCL is associated with a range of neurological and cardiovascular side effects, including fatigue, dizziness, and heart rate changes.
The drug is linked to decreased white blood cell counts and lymphocyte counts, indicating potential immunosuppressive effects. There are reports of serious adverse events, including falls, respiratory issues, and infections, which account for a significant portion of the total reports.
Patients taking Fingolimod Hcl should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Fingolimod HCL can cause bradycardia and hypotension, and patients should be monitored for these effects, especially when starting or adjusting the dose. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Fingolimod Hcl received a safety concern score of 65/100 (elevated concern). This is based on a 51.3% serious event ratio across 85,516 classified reports. The score accounts for 175,367 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 63,120, Male: 17,914, Unknown: 368. The most frequently reported age groups are age 49 (1,385 reports), age 40 (1,375 reports), age 41 (1,359 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 85,516 classified reports for FINGOLIMOD HCL:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Fingolimod HCL can cause bradycardia and hypotension, and patients should be monitored for these effects, especially when starting or adjusting the dose.
If you are taking Fingolimod Hcl, here are important things to know. The most commonly reported side effects include fatigue, multiple sclerosis relapse, headache, dizziness, white blood cell count decreased. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Patients should report any new or worsening symptoms to their healthcare provider immediately. Regular monitoring of blood pressure and heart rate is recommended, especially during the initial dosing period. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA continues to monitor the safety profile of Fingolimod HCL and has issued warnings regarding the risk of serious adverse events, particularly in patients with pre-existing cardiovascular conditions.
The FDA has received approximately 175,367 adverse event reports associated with Fingolimod Hcl. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Fingolimod Hcl include Fatigue, Multiple Sclerosis Relapse, Headache, Dizziness, White Blood Cell Count Decreased. By volume, the top reported reactions are: Fatigue (10,777 reports), Multiple Sclerosis Relapse (7,683 reports), Headache (7,231 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Fingolimod Hcl.
Out of 85,516 classified reports, 43,847 (51.3%) were classified as serious and 41,669 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Fingolimod Hcl break down by patient sex as follows: Female: 63,120, Male: 17,914, Unknown: 368. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Fingolimod Hcl adverse events are: age 49: 1,385 reports, age 40: 1,375 reports, age 41: 1,359 reports, age 46: 1,354 reports, age 50: 1,349 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Fingolimod Hcl adverse event reports is Novartis Pharmaceuticals Corporation. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Fingolimod Hcl include: Gait Disturbance, Hypoaesthesia, Lymphocyte Count Decreased, Fall, Nausea. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Fingolimod Hcl to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Fingolimod Hcl has a safety concern score of 65 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Fingolimod HCL is associated with a range of neurological and cardiovascular side effects, including fatigue, dizziness, and heart rate changes.
Key safety signals identified in Fingolimod Hcl's adverse event data include: Falls and mobility issues are common, suggesting a risk of increased fall risk in patients.. Decreased white blood cell counts and lymphocyte counts are key safety signals, indicating potential immunosuppressive effects.. Serious adverse events such as respiratory issues and infections are notable, highlighting the need for close monitoring.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Fingolimod HCL can cause bradycardia and hypotension, and patients should be monitored for these effects, especially when starting or adjusting the dose. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Fingolimod Hcl.
Patients should report any new or worsening symptoms to their healthcare provider immediately. Regular monitoring of blood pressure and heart rate is recommended, especially during the initial dosing period.
Fingolimod Hcl has 175,367 adverse event reports on file with the FDA. The drug is linked to decreased white blood cell counts and lymphocyte counts, indicating potential immunosuppressive effects. The volume of reports for Fingolimod Hcl reflects both the drug's usage level and the vigilance of the reporting community.
The FDA continues to monitor the safety profile of Fingolimod HCL and has issued warnings regarding the risk of serious adverse events, particularly in patients with pre-existing cardiovascular conditions. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Novartis Pharmaceuticals Corporation and compare their safety profiles:
The following drugs share commonly reported adverse reactions with FINGOLIMOD HCL:
Drugs related to FINGOLIMOD HCL based on therapeutic use, drug class, or shared indications: